CHIR-265
A substance being studied in the treatment of melanoma. CHIR-265 may block the growth of tumors and the growth of blood vessels from surrounding tissue to the tumor. It is a type of Raf kinase inhibitor and angiogenesis inhibitor.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.